Taisho Pharmaceutical Holdings Co (TSE:4581) Net Income (Continuing Operations) : 円10,917 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Taisho Pharmaceutical Holdings Co's Net Income (Continuing Operations) for the three months ended in Dec. 2023 was 円3,300 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was 円10,917 Mil.

Taisho Pharmaceutical Holdings Co Net Income (Continuing Operations) Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Net Income (Continuing Operations) Chart

Taisho Pharmaceutical Holdings Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

49,826.00

21,530.00

15,194.00

14,950.00

21,302.00

Taisho Pharmaceutical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial															10,686.00	-1,374.00	5,305.00	3,686.00	3,300.00

Taisho Pharmaceutical Holdings Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円10,917 Mil.

Taisho Pharmaceutical Holdings Co (TSE:4581) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Taisho Pharmaceutical Holdings Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

TAIPY:USA TAISF:USA

Address

3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655

Website

http://www.taisho-holdings.co.jp

Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines